This blinded, placebo-controlled study assessed symptom scores and treatment outcome two years (range 16 to 27 months) after a single treatment with NX-1207 or placebo.
For patients with prostate size <70 grams, the results showed that a statistically significant percentage of patients initially treated once with NX-1207 were not on benign prostatic hyperplasia (BPH) medication and had not required surgical intervention as compared to patients who received placebo. In this important population (which corresponds to the group for comparison with other drugs), the results showed that 60% of patients who received NX-1207 required no other BPH treatment, and had maintained an improvement of 11.3 points in BPH symptom score. After two years, 52% of patients treated with NX-1207 were not on BPH medication and had not required surgical intervention for their BPH since their initial treatment with NX-1207; these patients had a mean improvement of 10.2 points in AUA BPH symptom score values, the widely accepted scale used to assess the efficacy of BPH treatments. Paul Averback, CEO of Nymox, said: "This blinded clinical study demonstrates a striking degree of long-term improvement in BPH patients given a single treatment of NX-1207, and further confirms the promising results from the earlier completed US clinical trials. The durability of BPH symptom improvement from NX-1207 treatment is of special interest to potential marketing partners for NX-1207."